Bovine Pericardium held a 69.6% share of the aortic valve replacement devices market in 2025, maintaining its lead within leaflet material selection. This position is backed by its broad use across commercially established valve designs and the familiarity clinicians and manufacturers have with its handling and performance characteristics in valve construction. In the aortic valve replacement devices market, that combination of established integration into device portfolios and routine clinical acceptance helps sustain Bovine Pericardium’s leadership.

Porcine Pericardium is the fastest-growing leaflet material segment in the aortic valve replacement devices market as product development efforts continue to broaden material options beyond the long-dominant standard. Its growth momentum is tied to rising interest in alternative tissue configurations that can meet evolving design and procedural requirements, giving manufacturers and care providers greater flexibility than more entrenched material choices. Relative to established alternatives, Porcine Pericardium is experiencing stronger uptake because it aligns with ongoing innovation in valve design rather than relying on legacy adoption alone.

End-use Segment Analysis: Inpatient Facilities (Largest Segment) vs Outpatient Facilities (Fastest-Growing Segment)

In 2025, Inpatient Facilities accounted for an 87.59% share of the aortic valve replacement devices market, reflecting their central role in managing valve replacement procedures that require intensive perioperative care, specialist teams, and hospital-based monitoring. The segment’s leadership is maintained through the clinical complexity associated with aortic valve interventions, where access to operating infrastructure, post-procedure observation, and multidisciplinary support remains essential. Across the aortic valve replacement devices market, these operational requirements keep Inpatient Facilities as the dominant end-use setting.

Outpatient Facilities represent the fastest-growing end-use segment in the aortic valve replacement devices market as care delivery gradually shifts toward settings that can support selected procedures with greater efficiency and shorter patient stays. Their momentum is being backed by procedural streamlining and the broader push to reduce the burden on inpatient capacity where clinically appropriate. Compared with traditional hospital-based care, Outpatient Facilities are gaining ground because they better match the industry’s move toward less resource-intensive treatment pathways.